Abstract
Colorectal cancer is the second most common cause of cancer-related mortality in the west. The high incidence and mortality make effective prevention an important public-health and economic issue. The regular intake of aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs) has been associated with decreased incidence of certain types of cancer particularly those with an inflammatory component, and then are among the few agents known to be chemopreventive. Nitric oxide-releasing non-steroidal anti-inflammatory drugs (NO-NSAIDs) are new chemical entities obtained by adding a nitric oxide-releasing moiety to classical molecules. This new class of molecules has been demonstrated to be much more safe than NSAIDs due to their ability to reduce gastric toxicity. They could therefore represent an alternative to classical NSAIDs treatment. In this review, we sumarise the recent findings in the mechanisms and pathways involved in the antitumoral effects of both NSAIDs and NO-NSAIDs as well as the clinical trials performed with these compounds.
Keywords: nitric oxide-releasing non steroidal anti-inflammatory drugs, anti-tumoral molecules, colorectal cancer, cancer-related mortality, nsaids, no-nsaids, nitric oxide-releasing moiety
Current Cancer Drug Targets
Title: Nitric Oxide-Releasing Non Steroidal Anti-Inflammatory Drugs: A New Generation of Anti-Tumoral Molecules
Volume: 3 Issue: 6
Author(s): Christian Lavagna, Piero Del Soldato, Jean-Luc Burgaud and Patrick Rampal
Affiliation:
Keywords: nitric oxide-releasing non steroidal anti-inflammatory drugs, anti-tumoral molecules, colorectal cancer, cancer-related mortality, nsaids, no-nsaids, nitric oxide-releasing moiety
Abstract: Colorectal cancer is the second most common cause of cancer-related mortality in the west. The high incidence and mortality make effective prevention an important public-health and economic issue. The regular intake of aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs) has been associated with decreased incidence of certain types of cancer particularly those with an inflammatory component, and then are among the few agents known to be chemopreventive. Nitric oxide-releasing non-steroidal anti-inflammatory drugs (NO-NSAIDs) are new chemical entities obtained by adding a nitric oxide-releasing moiety to classical molecules. This new class of molecules has been demonstrated to be much more safe than NSAIDs due to their ability to reduce gastric toxicity. They could therefore represent an alternative to classical NSAIDs treatment. In this review, we sumarise the recent findings in the mechanisms and pathways involved in the antitumoral effects of both NSAIDs and NO-NSAIDs as well as the clinical trials performed with these compounds.
Export Options
About this article
Cite this article as:
Lavagna Christian, Soldato Del Piero, Burgaud Jean-Luc and Rampal Patrick, Nitric Oxide-Releasing Non Steroidal Anti-Inflammatory Drugs: A New Generation of Anti-Tumoral Molecules, Current Cancer Drug Targets 2003; 3 (6) . https://dx.doi.org/10.2174/1568009033481750
DOI https://dx.doi.org/10.2174/1568009033481750 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
MicroRNA-21: From Cancer to Cardiovascular Disease
Current Drug Targets An Overview on Keratinocyte Growth Factor: From the Molecular Properties to Clinical Applications
Protein & Peptide Letters Emerging Therapies Targeting Tumor Vasculature in Multiple Myeloma and other Hematologic and Solid Malignancies
Current Cancer Drug Targets Fighting Fire with Fire: A Patent for the Combined Application of Oncolytic Herpes Viruses and Antiangiogenic Agents in the Battle Against Human Cancers
Recent Patents on Anti-Cancer Drug Discovery The HGF-Met Signaling Axis: Emerging Themes and Targets of Inhibition
Current Protein & Peptide Science Patent Selections
Recent Patents on Inflammation & Allergy Drug Discovery Targeting Receptor Tyrosine Kinases Using Monoclonal Antibodies: The Most Specific Tools for Targeted-Based Cancer Therapy
Current Drug Targets Angiogenesis and Angiogenesis Inhibitors: a New Potential Anticancer Therapeutic Strategy
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Targeting Tumor Necrosis Factor Alpha for Alzheimer’s Disease
Current Alzheimer Research Indoleamine 2,3-dioxygenase, Tregs and Cancer
Current Medicinal Chemistry Programmed Cell Death Mechanisms in Neurological Disease
Current Molecular Medicine Prostate Cancer Prevention in the Developing World - What are we Waiting for?
Current Pharmacogenomics and Personalized Medicine Applications of Circadian Metabolomics
Current Metabolomics Role of MMPs in Metastatic Dissemination: Implications for Therapeutic Advances
Current Pharmaceutical Biotechnology Human Platelets Express Authentic CB1 and CB2 Receptors
Current Neurovascular Research Pioglitazone Prevents Smoking Carcinogen-Induced Lung Tumor Development in Mice
Current Cancer Drug Targets Role of Isoprenoid Compounds on Angiogenic Regulation: Opportunities and Challenges
Current Medicinal Chemistry Recent Advances in Health Promoting Effect of Dietary Polyphenols
Current Nutrition & Food Science The Urokinase Receptor as a Potential Target in Cancer Therapy
Current Pharmaceutical Design Ganoderma lucidum (Ling-zhi): The Impact of Chemistry on Biological Activity in Cancer
Current Bioactive Compounds